Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07008378 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

A Phase 1 study of Multiple Sclerosis, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT07008378: Recruiting Phase 1 study of Multiple Sclerosis, sponsored by Genentech.

NCT07008378 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by Genentech. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07008378, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

Conditions Studied

Multiple Sclerosis

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • BIOLOGICAL P-CD19CD20-ALLO1 Cells

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-15
Est. Completion 2032-08-31
Phase Phase 1
Genentech

332 total trials

What NCT07008378 shows while recruiting

NCT07008378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT07008378 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT07008378 about?

NCT07008378 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis". This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

What is the current status of trial NCT07008378?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-15. Estimated completion is 2032-08-31.

What conditions does trial NCT07008378 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07008378?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), P-CD19CD20-ALLO1 Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT07008378?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07008378 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07008378's enrollment target sits among peer trials

60 159th of 315 higher than 146 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07008378

Source: ClinicalTrials.gov NCT07008378, the US trial registry maintained by the National Library of Medicine. NCT07008378 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.